🇺🇸 FDA
Patent

US 12139546

Methods of treating urea cycle disorders by interfering with glucagon receptor signaling

granted A61KA61K2039/505A61K31/7088

Quick answer

US patent 12139546 (Methods of treating urea cycle disorders by interfering with glucagon receptor signaling) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/505, A61K31/7088, A61K45/06, A61P